Hyperlipidaemia

Medicine (United Kingdom)

Volumn 41, Issue 10, 2013, Pages 607-609

  Hlaing, Thinn Thinn ^a   Park, Adrian ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

coronary vascular disease; hypercholesterolaemia; hyperlipidaemia; hypertriglyceridaemia; statins

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CHYLOMICRON; CREATINE KINASE; EZETIMIBE; FIBRIC ACID DERIVATIVE; FISH OIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 ACID ETHYL ESTER; ROSUVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ALCOHOL ABUSE; APHERESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DIET; DRUG MEGADOSE; EXERCISE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPERTRIGLYCERIDEMIA; FAMILY HISTORY; FIRST DEGREE RELATIVE; HEART PROTECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 1; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIFESTYLE; LIVER TRANSPLANTATION; LOW FAT DIET; MEDICAL HISTORY; PATHOGENESIS; POLYGENIC HYPERCHOLESTEROLEMIA; PRIMARY PREVENTION; PRIORITY JOURNAL; REMNANT HYPERLIPOPROTEINEMIA; REVIEW; SECOND DEGREE RELATIVE; SECONDARY PREVENTION; SMOKING; VASCULITIS;

EID: 84885442678     PISSN: 13573039     EISSN: 13654357     Source Type: Journal    
DOI: 10.1016/j.mpmed.2013.07.004     Document Type: Review

References (12)

1. The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice Eur Heart J 33 2012 1635 1701
2. B.R. Haymore, J.R. Parks, T.G. Oliver, and B.C. Glister Hypertriglyceridemia Hosp Physician 41 3 2005 17 24
3. P.N. Durrington Familial hypercholesterolaemia Heart 2009 10.1136/hrt.2008.156943
4. J.H. Contois Apolipoprotein B and cardiovascular disease risk: position statement from the AACC lipoproteins and vascular diseases division working group on best practices Clin Chem 55 3 2009 407 419
5. National Institute for Health and Clinical Excellence. NICE clinical guideline 67. Lipid modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Available at: www.nice.org.uk/CG067.
6. D. Bhatnager, H. Soran, and P.N. Durrington Treatment of hyperlipidaemia Br Med J 337 2008 503 508
7. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group Br Med J 303 1991 893 896
8. W.J. Marshall, and S.K. Bangert Clincal biochemistry metabolic and clinical aspects 2nd ed. 2008 Elsevier Limited Churchill Livingstone
9. D. Vodnala, M. Rubenfire, and R. Brook Secondary causes of dyslipidaemia Am J Cardiol 110 2012 823 825
10. C.J. Fichtenbaum Coronary heart disease risk, dyslipidemia, and management in HIV-infected persons HIV Clin Trials 5 2004 416 433
11. P.W. Mallon Antiretroviral therapy and dyslipidaemia: unlocking the code PLoS Med 3 2006 e85
12. M. Olfson, S.C. Marcus, P. Corey-Lisle, A.V. Tuomari, P. Hines, and G.J. L'Italien Hyperlipidemia following treatment with antipsychotic medications Am J Psychiatry 163 2006 1821 1825